These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 4276489)

  • 21. Ca overload as the determinant factor in the production of catecholamine-induced myocardial lesions.
    Fleckenstein A; Janke J; Döring HJ; Pachinger O
    Recent Adv Stud Cardiac Struct Metab; 1973; 2():455-66. PubMed ID: 4806979
    [No Abstract]   [Full Text] [Related]  

  • 22. [Hypertensive cardiopathy: a new physiopathological and clinical classification].
    Iriarte Ezkurdia M; Eizaga Etxebarria NM; Morillas Bueno M; Sagastagoitia Gorostiza JD
    Rev Esp Cardiol; 1991 Mar; 44(3):141-52. PubMed ID: 1828605
    [No Abstract]   [Full Text] [Related]  

  • 23. Insufficiency of hypertrophied heart.
    Meerson FZ
    Basic Res Cardiol; 1976; 71(4):343-54. PubMed ID: 135557
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Early metabolic alterations during the development of experimentally induced cardiac hypertrophy.
    Zimmer HG; Gerlach E
    Arzneimittelforschung; 1980; 30(11a):2001-7. PubMed ID: 6452127
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiac fatty acid uptake and transport in health and disease.
    van der Vusse GJ; van Bilsen M; Glatz JF
    Cardiovasc Res; 2000 Jan; 45(2):279-93. PubMed ID: 10728348
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The mechanism of hypertrophy and wear of the myocardium.
    Meerson FZ; Pshennikova MG
    Acta Cardiol; 1965; 20(5):381-91. PubMed ID: 4158561
    [No Abstract]   [Full Text] [Related]  

  • 27. Overview on pathogenesis of cardiac hypertrophy.
    Rabinowitz M
    Circ Res; 1974 Aug; 35(2):suppl II:3-11. PubMed ID: 4367295
    [No Abstract]   [Full Text] [Related]  

  • 28. [Heart hypertrophy and cardiac insufficiency from the viewpoint of modern pathology].
    Büchner F
    Dtsch Med Wochenschr; 1971 Jan; 96(4):146-52 passim. PubMed ID: 4923988
    [No Abstract]   [Full Text] [Related]  

  • 29. Differences between pathological and physiological cardiac hypertrophy: novel therapeutic strategies to treat heart failure.
    McMullen JR; Jennings GL
    Clin Exp Pharmacol Physiol; 2007 Apr; 34(4):255-62. PubMed ID: 17324134
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ischemic preconditioning prevents reperfusion heart injury in cardiac hypertrophy by activation of mitochondrial KATP channels.
    Rajesh KG; Sasaguri S; Suzuki R; Xing Y; Maeda H
    Int J Cardiol; 2004 Jul; 96(1):41-9. PubMed ID: 15203260
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Physiopathologic modifications in the myocardial levels of adenine nucleotides].
    Rossi A; Aussedat J; Lavanchy N
    Diabete Metab; 1984 Oct; 10(4):260-74. PubMed ID: 6239798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mechanical and biochemical correlates of cardiac hypertrophy.
    Alpert NR; Hamrell BB; Halpern W
    Circ Res; 1974 Aug; 35(2):suppl II:71-82. PubMed ID: 4276491
    [No Abstract]   [Full Text] [Related]  

  • 33. Effects of potassium-glucose-insulin treatment on the histology, protein synthesis, and mechanical activity of the myopathic hamster heart.
    Lochner A; Van Der Walt JJ; Bajusz E; Brink A; Kotze JC
    Recent Adv Stud Cardiac Struct Metab; 1973; 2():543-55. PubMed ID: 4806986
    [No Abstract]   [Full Text] [Related]  

  • 34. [Alcoholic myocardiopathy].
    Amelung D
    Verh Dtsch Ges Inn Med; 1971; 77():365-74. PubMed ID: 4949760
    [No Abstract]   [Full Text] [Related]  

  • 35. Left ventricular hypertrophy in clinical practice: cardiomyopathies.
    Kuhn H
    Eur Heart J; 1982 Apr; 3 Suppl A():187-92. PubMed ID: 6210545
    [No Abstract]   [Full Text] [Related]  

  • 36. Cardiac hypertrophy and heart failure: dynamics of changes in proteins and nucleic acids.
    Fizelova A; Fizel A
    J Mol Cell Cardiol; 1970 Dec; 1(4):389-402. PubMed ID: 4255340
    [No Abstract]   [Full Text] [Related]  

  • 37. The PTHrP/PTH.1-R bioregulation system in cardiac hypertrophy: possible therapeutic implications.
    Halapas A; Diamanti-Kandarakis E; Kremastinos D; Koutsilieris M
    In Vivo; 2006; 20(6B):837-44. PubMed ID: 17203776
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Morphological principles of cardiac hypertrophy].
    Knieriem HJ
    Verh Dtsch Ges Kreislaufforsch; 1972; 38():1-21. PubMed ID: 4268341
    [No Abstract]   [Full Text] [Related]  

  • 39. Is the ATP decline a signal for stimulating protein synthesis in isoproterenol-induced cardiac hypertrophy?
    Zimmer HG; Steinkopff G; Ibel H; Koschine H
    J Mol Cell Cardiol; 1980 Apr; 12(4):421-6. PubMed ID: 6445987
    [No Abstract]   [Full Text] [Related]  

  • 40. Relationships among hypertrophy, hypertension, and coronary arterial patterns, and pharmacological responses in cardiomyopathies.
    Goodwin JF
    Recent Adv Stud Cardiac Struct Metab; 1973; 3():431-54. PubMed ID: 4283193
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.